To be eligible, a patient must have documented confirmation of a PHEX pathogenic variant or have a confirmed diagnosis of XLH presenting with (1) low serum phosphate, (2) current or historical radiographic evidence of rickets, (3) elevated serum or plasma FGF23, and (4) renal phosphate wasting. Here, FGF23 is linked to X-linked hypophosphatemia.